Common diplotypesb | Expected population frequency, %c | PK/PD phenotype | Clinical phenotype | FDA guidelines | ||
---|---|---|---|---|---|---|
 | Caucasian ancestry | African ancestry | East Asian ancestry |  |  |  |
CYP2C9*1/*1 | 67 | 84.5 | 92 | EM: normal enzymatic function and drug elimination | Expected to have a normal analgesic response at standard dose of celecoxib. Colorectal adenoma treatment: no additional efficacy with 400 mg celecoxib twice daily compared with 200 mg twice daily | – |
CY2C9*1/*2, CYP2C1/*3, and other rare diplotypes (see Additional file 1: Table S10) | 30 | 15 | 8 | Likely IM: reduced enzymatic function and drug elimination, leading to increased drug exposure | Insufficient data; predicted risk of side effects is unknown | – |
CYP2C9*3/*3, CYP2C*2/*3, CYP2C*2/*2, and other rare diplotypes (see Additional file 1: Table S10) | 3 | 0.6 | 0.2 | PM: greatly reduced enzymatic function and drug elimination, leading to greater drug exposure | Greater risk of adverse cardiovascular events with 400 mg celecoxib twice daily. Colorectal adenoma treatment: decreased recurrence with 400 mg celecoxib twice daily | Consider 50% of the standard starting dose in PMs; consider alternative treatment in PMs with juvenile rheumatoid arthritis |